Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice